JP Morgan 2025: analysts remain doubtful of Illumina’s growth
It’s been a busy week for Illumina at the JP Morgan 2025 Healthcare conference, with the company revealing partnerships and…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a trainee reporter for Medical Device Network, covering developments in the healthcare sector. Coming from a scientific and medical background, Robert has reported across various topics with expertise in neuroscience, genetics, and epidemiology. Previously, he worked on a freelance basis with New Scientist.
-
-
WHO reports eight deaths from suspected Marburg outbreak in Tanzania
Eight people have likely died from an outbreak of Marburg virus disease (MVD) in a northwestern region of Tanzania, according…
-
JP Morgan 2025: Dexcom shares up 5% after 2025 outlook forecasts $4.6bn in revenue
Dexcom has shaken off the lower sales outlook that plagued its share price in 2024 as the diabetes device developer…
-
Illumina and Regeneron invest $139.5m in Truveta to build largest genetic database
DNA sequencing company Illumina and biotech Regeneron have invested in electronic health record data company Truveta to create the largest…
-
JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic
In moves that continue to strengthen its affiliation with the healthcare industry, NVIDIA has added three new companies to its…
-
Revvity wins FDA clearance for ChLIA assay in free testosterone measurement
The US Food and Drug Administration (FDA) has cleared Revvity’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. The authorisation…
-
Amwell divests virtual psychiatric care business for $21m to boost cash flow
Amwell has sold its virtual psychiatric care business, Amwell Psychiatric Care (APC), to telehealth company Avel eCare for around $21m.…
-
FIRE1 secures $120m in funding for heart failure sensor
FIRE1 has raised $120m in a financing round to advance its sensor that monitors important warning signs of heart failure…
-
Alleviant Medical wins IDE for no-implant atrial shunt device pivotal trial
The US Food and Drug Administration (FDA) has granted Alleviant Medical an investigational device exemption (IDE), enabling the company to…
-
NanoVibronix “achieves goals” of US trial pilot phase with UroShield
NanoVibronix has completed the first phase of a randomised control trial with UroShield, the company’s disposable ultrasound device designed to…